Close Menu
May 20, 2020
Sponsored by
Arbor Biosciences

Targeted NGS of SARS-CoV-2 with Swift RNA + Arbor Biosciences myBaits panel

Partner Webinar

Join or Log in for Access

This content is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The emergence of COVID-19 has resulted in the need for NGS strategies for characterizing the SARS-CoV-2 viral genome. Sequencing of the full-length genome is critical for identifying mutational variants and contributing to research in the fields of virology, immunology, epidemiology, and molecular evolution, among others. However, maximizing viral RNA sequencing reads from clinical samples can be challenging, particularly due to the amount of human background that may be present.

Sponsored by

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

Time magazine looks into how liquid biopsies are changing cancer care.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.

Oct
08
Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.